Lung Cancer Genotype-Based Therapy and Predictive Biomarkers: Present and Future
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lung Cancer Genotype-Based Therapy and Predictive Biomarkers: Present and Future
Authors
Keywords
-
Journal
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
Volume 136, Issue 12, Pages 1482-1491
Publisher
Archives of Pathology and Laboratory Medicine
Online
2012-11-30
DOI
10.5858/arpa.2012-0508-ra
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Suitability of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Specimens for Subtyping and Genotyping of Non–Small Cell Lung Cancer
- (2012) Neal Navani et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Advances in Treatment of Lung Cancer With Targeted Therapy
- (2012) Philip T. Cagle et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Napsin A, a New Marker for Lung Adenocarcinoma, Is Complementary and More Sensitive and Specific Than Thyroid Transcription Factor 1 in the Differential Diagnosis of Primary Pulmonary Carcinoma: Evaluation of 1674 Cases by Tissue Microarray
- (2012) Bradley M. Turner et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells
- (2012) Xiaoying Liu et al. BIOCHEMICAL PHARMACOLOGY
- Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules
- (2012) T Shimokawa et al. BRITISH JOURNAL OF CANCER
- Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells
- (2012) J Tanizaki et al. BRITISH JOURNAL OF CANCER
- The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers
- (2012) A J Atherly et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Key Principles and Clinical Applications of "Next-Generation" DNA Sequencing
- (2012) J. M. Rizzo et al. Cancer Prevention Research
- Identification of RET gene fusion by exon array analyses in “pan-negative” lung cancer from never smokers
- (2012) Fei Li et al. CELL RESEARCH
- Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non-Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion
- (2012) V. M. Rimkunas et al. CLINICAL CANCER RESEARCH
- Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819
- (2012) M. W. Redman et al. CLINICAL CANCER RESEARCH
- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations
- (2012) N. Rekhtman et al. CLINICAL CANCER RESEARCH
- Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer
- (2012) Giorgio V. Scagliotti et al. Clinical Lung Cancer
- Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis
- (2012) Robert L Yauch et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- The positive impact of cytological specimens for EGFR mutation testing in non-small cell lung cancer: a single South East Asian laboratory’s analysis of 670 cases
- (2012) B. Pang et al. CYTOPATHOLOGY
- Prognostic and Predictive Value of K-RAS Mutations in Non-Small Cell Lung Cancer
- (2012) Raffaele Califano et al. DRUGS
- Clinical Outcomes with Erlotinib in Patients with Epidermal Growth Factor Receptor Mutation
- (2012) Tony S.K. Mok et al. DRUGS
- Crizotinib in the treatment of non-small-cell lung cancer
- (2012) Patrick M Forde et al. EXPERT OPINION ON PHARMACOTHERAPY
- Cetuximab in non-small-cell lung cancer
- (2012) Guido Carillio et al. Expert Review of Anticancer Therapy
- ROS1 as a ‘druggable’ receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway
- (2012) Sai-Hong Ignatius Ou et al. Expert Review of Anticancer Therapy
- Routine EGFR and KRAS Mutation analysis using COLD-PCR in non-small cell lung cancer
- (2012) A. Pennycuick et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
- (2012) Cesare Gridelli et al. JOURNAL OF CLINICAL ONCOLOGY
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- ROS1 Rearrangements in Lung Cancer: A New Genomic Subset of Lung Adenocarcinoma
- (2012) Pasi A. Jänne et al. JOURNAL OF CLINICAL ONCOLOGY
- Drug Approvals 2011: Focus on Companion Diagnostics
- (2012) M. Goozner JNCI-Journal of the National Cancer Institute
- EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy
- (2012) Michele Milella et al. Journal of Thoracic Oncology
- Phase II Study of the Multitargeted Tyrosine Kinase Inhibitor XL647 in Patients with Non–Small-Cell Lung Cancer
- (2012) M. Catherine Pietanza et al. Journal of Thoracic Oncology
- Brief Report: A Phase II “Window-of-Opportunity” Frontline Study of the mTOR Inhibitor, Temsirolimus Given as a Single Agent in Patients with Advanced NSCLC, an NCCTG Study
- (2012) Thanyanan Reungwetwattana et al. Journal of Thoracic Oncology
- Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer
- (2012) Hiroyuki Yasuda et al. Journal of Thoracic Oncology
- Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping
- (2012) Geoffrey R. Oxnard et al. Journal of Thoracic Oncology
- A new generation of EGFR tyrosine-kinase inhibitors in NSCLC
- (2012) Fred R Hirsch et al. LANCET ONCOLOGY
- Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
- (2012) Vincent A Miller et al. LANCET ONCOLOGY
- Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
- (2012) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- EGFR–TKI resistant non-small cell lung cancer (NSCLC): New developments and implications for future treatment
- (2012) Wolfram Brugger et al. LUNG CANCER
- Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study
- (2012) R. Pirker et al. LUNG CANCER
- Detection of EML4-ALK fusion genes in a few cancer cells from transbronchial cytological specimens utilizing immediate cytology during bronchoscopy
- (2012) Nobuhiro Kanaji et al. LUNG CANCER
- Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma
- (2012) Adnan Hasanovic et al. LUNG CANCER
- The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor
- (2012) Y. Kim et al. MOLECULAR CANCER THERAPEUTICS
- Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
- (2012) Doron Lipson et al. NATURE MEDICINE
- KIF5B-RET fusions in lung adenocarcinoma
- (2012) Takashi Kohno et al. NATURE MEDICINE
- RET, ROS1 and ALK fusions in lung cancer
- (2012) Kengo Takeuchi et al. NATURE MEDICINE
- Multi-Level Targeting of the Phosphatidylinositol-3-Kinase Pathway in Non-Small Cell Lung Cancer Cells
- (2012) Christopher R. Zito et al. PLoS One
- KLC1-ALK: A Novel Fusion in Lung Cancer Identified Using a Formalin-Fixed Paraffin-Embedded Tissue Only
- (2012) Yuki Togashi et al. PLoS One
- Personalized Pathway Enrichment Map of Putative Cancer Genes from Next Generation Sequencing Data
- (2012) Peilin Jia et al. PLoS One
- Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications
- (2012) Antonio Marchetti et al. PLoS One
- Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts
- (2012) X. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies
- (2012) Arne Warth et al. VIRCHOWS ARCHIV
- Tackling Formalin-Fixed, Paraffin-Embedded Tumor Tissue with Next-Generation Sequencing
- (2012) Christopher L. Corless et al. Cancer Discovery
- Deep Sequence Analysis of Non-Small Cell Lung Cancer: Integrated Analysis of Gene Expression, Alternative Splicing, and Single Nucleotide Variations in Lung Adenocarcinomas with and without Oncogenic KRAS Mutations
- (2012) Krishna R. Kalari et al. Frontiers in Oncology
- Use of CT-guided fine needle aspiration biopsy in epidermal growth factor receptor mutation analysis in patients with advanced lung cancer
- (2011) Yi-Ping Zhuang et al. ACTA RADIOLOGICA
- Adenosquamous Carcinoma of the Lung
- (2011) Naobumi Tochigi et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis
- (2011) E. Bria et al. ANNALS OF ONCOLOGY
- Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
- (2011) L. V. Sequist et al. ANNALS OF ONCOLOGY
- Lung Carcinoma Morphology or Mutational Profile: That Is the Question
- (2011) Sanja Dacic ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Sorafenib induces apoptotic cell death in human non-small cell lung cancer cells by down-regulating mammalian target of rapamycin (mTOR)-dependent survivin expression
- (2011) Young-Sun Kim et al. BIOCHEMICAL PHARMACOLOGY
- Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology
- (2011) Maureen Cronin et al. Biomarkers in Medicine
- Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4)
- (2011) H. Murakami et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- EGFR mutation testing in nonsmall cell lung cancer patients by using cytology specimens
- (2011) Ignacio Gil-Bazo et al. CANCER CYTOPATHOLOGY
- EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects
- (2011) Jean-Charles Soria et al. CANCER TREATMENT REVIEWS
- Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the EGFR Gene
- (2011) N. A. Rizvi et al. CLINICAL CANCER RESEARCH
- EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma
- (2011) M. He et al. CLINICAL CANCER RESEARCH
- Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
- (2011) M. E. Arcila et al. CLINICAL CANCER RESEARCH
- Current Management of Small Cell Lung Cancer
- (2011) Joel W. Neal et al. CLINICS IN CHEST MEDICINE
- A Decade of Advances in Treatment of Early-Stage Lung Cancer
- (2011) Luca Paoletti et al. CLINICS IN CHEST MEDICINE
- Role of Genotyping in Non-Small Cell Lung Cancer Treatment
- (2011) Laura Bonanno et al. DRUGS
- Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma
- (2011) N. Girard et al. EUROPEAN RESPIRATORY JOURNAL
- The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patients
- (2011) Tim J Kruser et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer
- (2011) Giulio Metro et al. Expert Review of Anticancer Therapy
- Afatinib (BIBW 2992) development in non-small-cell lung cancer
- (2011) Vera Hirsh Future Oncology
- A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing
- (2011) Y. S. Ju et al. GENOME RESEARCH
- Personalized medicine for lung cancer: new challenges for pathology
- (2011) Keith M Kerr HISTOPATHOLOGY
- A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non–Small-Cell Lung Cancer
- (2011) Fred R. Hirsch et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
- (2011) Masahiro Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer
- (2011) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Incidence ofEGFRExon 19 Deletions and L858R in Tumor Specimens From Men and Cigarette Smokers With Lung Adenocarcinomas
- (2011) Sandra P. D'Angelo et al. JOURNAL OF CLINICAL ONCOLOGY
- 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
- (2011) Christopher G. Azzoli et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC: Figure 1
- (2011) Kathy Gately et al. JOURNAL OF CLINICAL PATHOLOGY
- Maintenance therapy in NSCLC: why? To whom? Which agent?
- (2011) Silvia Novello et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research
- (2011) Maria Bonomi et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer
- (2011) Zengliu Su et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Low-Dose Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations
- (2011) Hironori Satoh et al. Journal of Thoracic Oncology
- Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib
- (2011) Melissa L. Johnson et al. Journal of Thoracic Oncology
- A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer
- (2011) Peter M. Ellis et al. Journal of Thoracic Oncology
- Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for an Effective Screening Strategy for These Tumors
- (2011) Youngil Koh et al. Journal of Thoracic Oncology
- Correlation of IHC and FISH for ALK Gene Rearrangement in Non-small Cell Lung Carcinoma: IHC Score Algorithm for FISH
- (2011) Eunhee S. Yi et al. Journal of Thoracic Oncology
- Everolimus in Combination with Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with Chemotherapy: A Phase I Study Using a Novel, Adaptive Bayesian Dose-Escalation Model
- (2011) Johan Vansteenkiste et al. Journal of Thoracic Oncology
- Subtyping of Non-small Cell Lung Carcinoma: A Comparison of Small Biopsy and Cytology Specimens
- (2011) Carlie S. Sigel et al. Journal of Thoracic Oncology
- Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort
- (2011) Seiji Yano et al. Journal of Thoracic Oncology
- Suitability of Thoracic Cytology for New Therapeutic Paradigms in Non-small Cell Lung Carcinoma: High Accuracy of Tumor Subtyping and Feasibility of EGFR and KRAS Molecular Testing
- (2011) Natasha Rekhtman et al. Journal of Thoracic Oncology
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
- (2011) William D. Travis et al. Journal of Thoracic Oncology
- EGFR-Mutant Lung Adenocarcinomas Treated First-Line with the Novel EGFR Inhibitor, XL647, Can Subsequently Retain Moderate Sensitivity to Erlotinib
- (2011) Juliann Chmielecki et al. Journal of Thoracic Oncology
- XL647—A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding to Treatment with Either Gefitinib or Erlotinib
- (2011) M. Catherine Pietanza et al. Journal of Thoracic Oncology
- Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study
- (2011) Kenneth J O'Byrne et al. LANCET ONCOLOGY
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
- (2011) Alice T Shaw et al. LANCET ONCOLOGY
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
- (2011) Robert Pirker et al. LANCET ONCOLOGY
- Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens
- (2011) Natasha Rekhtman et al. MODERN PATHOLOGY
- p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma
- (2011) Justin A Bishop et al. MODERN PATHOLOGY
- The Role of Irreversible HER Family Inhibition in the Treatment of Patients with Non-Small Cell Lung Cancer
- (2011) E. Kwak ONCOLOGIST
- The Combination of RAD001 and NVP-BEZ235 Exerts Synergistic Anticancer Activity against Non-Small Cell Lung Cancer In Vitro and In Vivo
- (2011) Cheng-Xiong Xu et al. PLoS One
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
- (2011) R. Katayama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pathological Diagnosis and Classification of Lung Cancer in Small Biopsies and Cytology: Strategic Management of Tissue for Molecular Testing
- (2011) William Travis et al. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
- Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non-Small Cell Lung Cancers
- (2011) H. W. Cheung et al. Cancer Discovery
- The BATTLE Trial: Personalizing Therapy for Lung Cancer
- (2011) Edward S. Kim et al. Cancer Discovery
- Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond
- (2011) Sai-Hong Ignatius Ou Drug Design Development and Therapy
- Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities
- (2011) Elizabeth M. Gaughan et al. Therapeutic Advances in Medical Oncology
- The potential for crizotinib in non-small cell lung cancer: a perspective review
- (2011) Yung-Jue Bang Therapeutic Advances in Medical Oncology
- c-MET as a potential therapeutic target and biomarker in cancer
- (2011) J. Rafael Sierra et al. Therapeutic Advances in Medical Oncology
- Dual inhibition of EGFR and mTOR pathways in small cell lung cancer
- (2010) K Schmid et al. BRITISH JOURNAL OF CANCER
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer
- (2010) Suresh S. Ramalingam et al. CANCER
- Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation
- (2010) Kenichi Suda et al. CANCER AND METASTASIS REVIEWS
- Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer
- (2010) A. Tarhini et al. CLINICAL CANCER RESEARCH
- The Tissue Is the Issue: Personalized Medicine for Non-Small Cell Lung Cancer
- (2010) F. R. Hirsch et al. CLINICAL CANCER RESEARCH
- A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry
- (2010) M. Mino-Kenudson et al. CLINICAL CANCER RESEARCH
- A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
- (2010) E. B. Haura et al. CLINICAL CANCER RESEARCH
- Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
- (2010) Geoffrey R. Oxnard et al. CLINICAL CANCER RESEARCH
- Personalized medicine for non-small-cell lung cancer
- (2010) Tony S Mok et al. Expert Review of Anticancer Therapy
- Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis
- (2010) Luis Paz-Ares et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Personalizing Therapy in an Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor–Resistant Non–Small-Cell Lung Cancer Using PF-00299804 and Trastuzumab
- (2010) Ronan J. Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- Personalized Medicine in Non–Small-Cell Lung Cancer: IsKRASa Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy?
- (2010) Patrick J. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2010) Faye M. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Selection Design Trial of Concurrent Chemotherapy and Cetuximab Versus Chemotherapy Followed by Cetuximab in Advanced-Stage Non–Small-Cell Lung Cancer: Southwest Oncology Group Study S0342
- (2010) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- The Evolving Role of Histology in the Management of Advanced Non–Small-Cell Lung Cancer
- (2010) Corey J. Langer et al. JOURNAL OF CLINICAL ONCOLOGY
- A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples
- (2010) Gillian Ellison et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Assessment of EGFR Mutation Status in Lung Adenocarcinoma by Immunohistochemistry Using Antibodies Specific to the Two Major Forms of Mutant EGFR
- (2010) Marie Brevet et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: Report on initial experience and clinical utility at a single center
- (2010) Sandra P. D’Angelo et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- K-ras as a Target for Lung Cancer Therapy
- (2010) Alex A. Adjei Journal of Thoracic Oncology
- The International Epidemiology of Lung Cancer: Geographical Distribution and Secular Trends
- (2010) Danny R. Youlden et al. Journal of Thoracic Oncology
- Biomarkers Are Here to Stay for Clinical Research and Standard Care
- (2010) Paul A. Bunn et al. Journal of Thoracic Oncology
- Pathologic Diagnosis of Advanced Lung Cancer Based on Small Biopsies and Cytology: A Paradigm Shift
- (2010) William D. Travis et al. Journal of Thoracic Oncology
- Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer
- (2010) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop
- (2010) Robert Pirker et al. Journal of Thoracic Oncology
- Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans
- (2010) J. Matthew Reinersman et al. Journal of Thoracic Oncology
- Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations
- (2010) Yelena Y. Janjigian et al. Journal of Thoracic Oncology
- New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer
- (2010) Robert C. Doebele et al. LUNG CANCER
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
- (2010) D Ercan et al. ONCOGENE
- Increased Risk of Serious Hemorrhage with Bevacizumab in Cancer Patients: A Meta-Analysis
- (2010) Sanjaykumar Hapani et al. ONCOLOGY
- Targeted therapy: An evolving world of lung cancer
- (2010) Kwok-Chi LAM et al. RESPIROLOGY
- Core Needle Lung Biopsy Specimens: Adequacy for EGFR and KRAS Mutational Analysis
- (2009) Stephen B. Solomon et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors
- (2009) J.-C. Soria et al. ANNALS OF ONCOLOGY
- Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer
- (2009) K. N. Syrigos et al. ANNALS OF ONCOLOGY
- KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer
- (2009) K. Takeuchi et al. CLINICAL CANCER RESEARCH
- Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non-Small-Cell Lung Cancer
- (2009) J. Yu et al. CLINICAL CANCER RESEARCH
- Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population
- (2009) S. J. Rodig et al. CLINICAL CANCER RESEARCH
- Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway
- (2009) Kim-Son H. Nguyen et al. Clinical Lung Cancer
- Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes
- (2009) Paul Wheatley-Price et al. CURRENT OPINION IN ONCOLOGY
- Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non–small cell lung carcinomas
- (2009) Jennifer M. Boland et al. HUMAN PATHOLOGY
- Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer
- (2009) Tony S.K. Mok et al. JOURNAL OF CLINICAL ONCOLOGY
- Retrospective Evaluation of the Clinical and Radiographic Risk Factors Associated With Severe Pulmonary Hemorrhage in First-Line Advanced, Unresectable Non–Small-Cell Lung Cancer Treated With Carboplatin and Paclitaxel Plus Bevacizumab
- (2009) Alan B. Sandler et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
- (2009) Christopher G. Azzoli et al. JOURNAL OF CLINICAL ONCOLOGY
- First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
- (2009) Akira Inoue et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
- (2009) David Jackman et al. JOURNAL OF CLINICAL ONCOLOGY
- Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
- (2009) Tudor Ciuleanu et al. LANCET
- EGFR testing in lung cancer is ready for prime time
- (2009) Fred R Hirsch et al. LANCET ONCOLOGY
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Small Cell Lung Cancer
- (2009) Taimur Sher et al. MAYO CLINIC PROCEEDINGS
- EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology and young onset
- (2009) Kentaro Inamura et al. MODERN PATHOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies
- (2009) G. Scagliotti et al. ONCOLOGIST
- Clinicopathologic and Molecular Features of Epidermal Growth Factor Receptor T790M Mutation and c-MET Amplification in Tyrosine Kinase Inhibitor-resistant Chinese Non-small Cell Lung Cancer
- (2009) Hua-Jun Chen et al. PATHOLOGY & ONCOLOGY RESEARCH
- Identification of Novel Isoforms of the EML4-ALK Transforming Gene in Non-Small Cell Lung Cancer
- (2008) Y. L. Choi et al. CANCER RESEARCH
- Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations
- (2008) S. Yano et al. CANCER RESEARCH
- Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer
- (2008) F. R. Hirsch et al. CLINICAL CANCER RESEARCH
- Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
- (2008) D. B. Costa et al. CLINICAL CANCER RESEARCH
- Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma
- (2008) J. Bean et al. CLINICAL CANCER RESEARCH
- Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
- (2008) J. A. Engelman et al. CLINICAL CANCER RESEARCH
- The role of gefitinib in the management of Asian patients with non-small cell lung cancer
- (2008) Alex Y Chang EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Differential Responses to Erlotinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Cancers With Acquired Resistance to Gefitinib Carrying the L747S or T790M Secondary Mutations
- (2008) Daniel B. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers
- (2008) Kentaro Inamura et al. Journal of Thoracic Oncology
- EGFR FISH versus mutation: Different tests, different end-points
- (2008) Federico Cappuzzo LUNG CANCER
- The Potential Role of mTOR Inhibitors in Non-Small Cell Lung Cancer
- (2008) C. Gridelli et al. ONCOLOGIST
- Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment
- (2008) Clorinda Schettino et al. Expert Review of Respiratory Medicine
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started